Identifying low GLP-1 as a feature of PD opens up new therapeutic opportunities to augment GLP-1 secretion in PD patients via non-pharmacologic microbiota-directed interventions (e.g., diet, prebiotics, and probiotics) to modify disease course and/or improve symptoms. This evidence concerns the gene GLP1R and Parkinson disease.